Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive respiratory disease. Arguably, the complex interplay between immune cell subsets, coupled with an incomplete understanding of disease pathophysiology, has hindered the development of successful therapies. Despite efforts to understand its pathophysiology and develop effective treatments, IPF remains a fatal disease, necessitating the exploration of new treatment options. Mesenchymal stromal/stem cell (MSC) therapy has shown promise in experimental models of IPF, but further investigation is needed to understand its therapeutic effect. This study aimed to assess the therapeutic effect of adipose-derived mesenchymal stem cells in a bleomycin-induced pulmonary fibrosis model. First, MSC cells were obtained from mice and characterized using flow cytometry and cell differentiation culture methods. Then adult C57BL/6 mice were exposed to endotracheal instillation of bleomycin and concurrently treated with MSCs for reversal models on day 14. Experimental groups were evaluated on days 14, 21, or 28. Additionally, lung fibroblasts challenged with TGF-β1 were treated with MSCs supernatant or MSCs to explore the mechanisms underlying of pulmonary fibrosis reversal. Mesenchymal stem cells were successfully isolated from mouse adipose tissue and characterized based on their differentiation ability and cell phenotype. The presence of MSCs or their supernatant stimulated the proliferation and migration of lung fibrotic cells. MSCs supernatant reduced lung collagen deposition, improved the Ashcroft score and reduced the gene and protein expression of lung fibrosis-related substances. Bleomycin-challenged mice exhibited severe septal thickening and prominent fibrosis, which was effectively reversed by MSCs treatment. MSC supernatant could suppress the TGF-β1/Smad signaling pathway and supernatant promotes fibroblast autophagy. In summary, this study demonstrates that MSCs supernatant treatment is as effective as MSCs in revert the core features of bleomycin-induced pulmonary fibrosis. The current study has demonstrated that MSCs supernatant alleviates the BLM-induced pulmonary fibrosis in vivo. In vitro experiments further reveal that MSC supernatant could suppress the TGF-β1/Smad signaling pathway to inhibit the TGF-β1-induced fibroblast activation, and promotes fibroblast autophagy by Regulating p62 expression. These findings contribute to the growing body of evidence supporting the therapeutic application of MSCs in cell therapy medicine for IPF.

Autophagy Inhibition Restores CD200 Expression under IL-1β Microenvironment in Placental Mesenchymal Stem Cells of Fetal Origin and Improves Its Pulmonary Fibrosis Therapeutic Potential.

182. Effects of Inflammation-Mediated Autophagy of Human Placental Mesenchymal Stem Cells of Fetal Origin on Their Immunomodulatory Properties and Therapeutic Potential in Bleomycin-Induced Pulmonary Fibrosis Models

Different Sources Of Mscs On Pulmonary Fibrosis In C57bl/6 Mice

Human Placental Mesenchymal Stem Cells of Fetal Origins-Alleviated Inflammation and Fibrosis by Attenuating MyD88 Signaling in Bleomycin-Induced Pulmonary Fibrosis Mice.

Mesenchymal stem cells-extracellular vesicles alleviate pulmonary fibrosis by regulating immunomodulators

Mesenchymal Stem Cells Inhibit Epithelial-to-Mesenchymal Transition by Modulating the IRE1 α Branch of the Endoplasmic Reticulum Stress Response

Therapeutic Effect and Location of GFP-Labeled Placental Mesenchymal Stem Cells on Hepatic Fibrosis in Rats

Human Placental Mesenchymal Stem Cells of Fetal Origin Relieves Mouse Pulmonary Fibrosis Via Downregulating MyD88 and TGF-β Signaling Pathway

Human Umbilical Cord Mesenchymal Stem Cells Inhibit Liver Fibrosis Via the Microrna-148A-5p/slit3 Axis

Adipose-derived mesenchymal stem cell therapy for reverse bleomycin-induced experimental pulmonary fibrosis

Mesenchymal stem cell therapy in pulmonary fibrosis: a meta-analysis of preclinical studies

Placental mesenchymal stem cells suppress inflammation and promote M2-like macrophage polarization through the IL-10/STAT3/NLRP3 axis in acute lung injury

Extracellular vesicles derived from umbilical cord mesenchymal stromal cells alleviate pulmonary fibrosis by means of transforming growth factor-β signaling inhibition

A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis

Different Roles of PD-L1 and FasL in Immunomodulation Mediated by Human Placenta-Derived Mesenchymal Stem Cells.

Interferon-γ Pretreated Human MSC Show Improved Efficiency in Humanized Mice Model of Pulmonary Fibrosis

hucMSC treatment ameliorated pulmonary fibrosis via downregulating the circFOXP1–HuR–EZH2/STAT1/FOXK1 autophagic axis

The Role of MicroRNAs in Mesenchymal Stem Cell–Based Modulation of Pulmonary Fibrosis

Material-driven immunomodulation and ECM remodeling reverse pulmonary fibrosis by local delivery of stem cell-laden microcapsules

Anti-fibrotic effects of different sources of MSC in bleomycin-induced lung fibrosis in C57BL6 male mice